Sachem Capital Corp. (SACH) Shareholders Re-elect Board
Get Alerts SACH Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 13.3%
Revenue Growth %: +6.0%
Join SI Premium – FREE
Sachem Capital Corp. (NYSE American: SACH) today announced that its 2021 Annual Meeting of Shareholders (the “Annual Meeting”), scheduled for Wednesday, October 13, 2021 at 10:00 a.m. Eastern Daylight Saving Time, was convened on Proposals 1 (election of directors), 3 (advisory approval of the appointment of auditors) and 4 (advisory approval of executive compensation), each as set forth in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on September 10, 2021 (the “Proxy Statement”), all of which were approved. Details of the vote will be available in the Company’s Form 8-K reporting the voting results of the Annual Meeting to be filed with the Securities and Exchange Commission and will be available on the Company’s website upon filing.
The Company adjourned the Annual Meeting with respect to Proposal 2, to amend its certificate of incorporation to increase the number of authorized capital shares of the Company. Approval of more than 50% of all outstanding common shares of the Company, as of August 30, 2021, is necessary for Proposal 2 to be approved. The adjournment will allow shareholders additional time to vote and allow the company to continue to solicit additional votes on Proposal 2. The Annual Meeting will resume virtually via the internet at https://meetnow.global/MUUP4LY with respect to Proposal 2 on Wednesday, November 3, 2021 at 10:00 a.m., Eastern Daylight Saving Time.
The Company encourages all shareholders of record as of August 30, 2021 who have not yet voted on Proposal 2, or who voted against Proposal 2, to vote to approve Proposal 2, by 11:59 PM Eastern Daylight Saving Time on November 2, 2021. Shareholders of record may vote their shares by calling InvestorCom at (877) 972-0090.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Standard Nuclear names former DOE nuclear policy chief to its board
- Mesoblast completes patient treatment in phase 3 back pain trial
- Daré Bioscience prices $6M direct offering at $1.37 per share
Create E-mail Alert Related Categories
Board ChangesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share